Latest News

Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.

Europe’s dermatology apps boom, but most lack clinical validation, CE/GDPR transparency, and inclusive AI training, raising safety and reliability concerns for patients.

Shawna Jones, PA-C, shares a road map to aesthetics, emphasizing clinical judgment, anatomy, patient trust, safety, and lifelong learning.

This review of the latest dermatological studies includes insights on multimodal imaging for rosacea evaluation, growth in pediatric AD patients, botulinum toxin for post-acne sequelae, and more.

Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.

Multidisciplinary experts rethink advanced cutaneous squamous cell carcinoma care, weighing immunotherapy options, trial data limits, adverse events, and smoother dermatology-oncology referrals.

New trials show oral collagen boosts hydration, elasticity and barrier strength in weeks—while wrinkle and dermal density claims remain unproven.

The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.

Real-world data show ruxolitinib cream improves facial vitiligo in 3 months, boosting quality of life and imaging-confirmed repigmentation.

The investigational anti–IL-13 monoclonal antibody could change how dermatologists think about biologic dosing in moderate to severe AD.

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are exosome-derived products legitimate or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.